Butalbital
A barbiturate with sedative properties, typically found in combination products used to treat tension headaches and migraines, often combined with acetaminophen and caffeine. It works by relaxing muscle contraction and producing central nervous system sedation. It carries a risk of medication-overuse headache and physical dependence with frequent use.
Molekularmasse
224,2600 g/mol
LogP
1,70
TPSA
75,30 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D-Struktur
Cite this structure
Embed this structure
SMILES
C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O
InChI
InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
Molecular Formula
C11H16N2O3
HBD / HBA
2 / 3
Rotierbare Bindungen
4
Schwere Atome
16
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A barbiturate with sedative properties, typically found in combination products used to treat tension headaches and migraines, often combined with acetaminophen and caffeine. It works by relaxing muscle contraction and producing central nervous system sedation. It carries a risk of medication-overuse headache and physical dependence with frequent use.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Butalbital is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL454. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2481. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="butalbital"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/butalbital/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/butalbital/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/butalbital/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="butalbital"></drugfyi-drug>